Is Relay Therapeutics a Buy After Promising Trial Results?

Relay Therapeutics reported promising phase 2 data for zovegalisib in vascular anomalies, with a volumetric response in about 60% of the 20 patients studied. The lead asset also has FDA breakthrough therapy designation in PI3Kα-mutant HR+/HER2- advanced breast cancer and showed a median progression-free survival of 11.1 months, while the company says its $642 million cash balance can fund operations well into 2029. Offsetting the clinical progress, Relay remains pre-revenue and highly dependent on future trial success, with 2026 consensus revenue estimated at just $9.84 million and losses of about $1.64 per share.

Analysis

The market is starting to price Relay less like a single-asset biotech and more like a platform with multiple shots on goal, but the key hidden effect is that positive vascular-anomaly data can materially improve the probability-of-success curve for the lead asset’s oncology program. That matters because rare-disease signals often travel faster into physician enthusiasm and payer credibility than oncology data, creating an earlier commercial validation path that can de-risk the broader franchise before the pivotal readout. The stock’s move likely reflects investors repricing not just the data, but the company’s ability to self-fund into the next major catalyst without dilution.

The bigger second-order winner may be Pfizer. Even though the collaboration is not the core story, any improved confidence in the PI3K pathway can raise the strategic value of combination regimens and expand the optionality around atirmociclib-like partners. Conversely, the most exposed group is the basket of late-stage, cash-poor biotech peers: Relay’s balance sheet gives it time, and time is the scarce asset in this segment. That can compress relative multiples for names that need capital markets access before data.

The risk is that investors extrapolate a small, heterogeneous phase 2 signal into a broad commercial thesis too early. Rare-disease response rates in 20 patients can be directionally important but still fragile; one safety issue or a less favorable signal in broader enrollment could unwind a large portion of the move within days. The more durable catalyst is the 2027 phase 3 initiation and subsequent registrational milestones, so the trade is fundamentally a months-to-years story rather than a near-term momentum chase.

Consensus appears to underweight how much cash changes management behavior: with runway into 2029, Relay can preserve pricing power in any future partnering or licensing discussions, rather than negotiating from a position of distress. That makes the equity less about bankruptcy risk and more about clinical execution optionality, which is why the move may be directionally justified even if the headline valuation is no longer cheap. The overhang is binary clinical risk, but the asymmetry improves if the market begins assigning value to the platform rather than just zovegalisib.

Key Decisions for Investors

• Long RLAY on pullbacks over the next 1-2 weeks; use a 6-12 month horizon. Risk/reward is favorable if the market continues to re-rate the platform, but size modestly because the equity remains binary around future trial design and safety.
• For higher-conviction exposure, buy RLAY Jan-2027 calls or call spreads. This captures the runway to the key pivotal-trial setup while limiting downside if the stock gives back the post-data spike.
• Pair trade: long RLAY / short a basket of cash-constrained clinical-stage biotechs over the next 3-6 months. The relative thesis is that balance-sheet strength is being newly rewarded, and names that must raise capital before data should underperform.
• Hold PFE as a low-beta beneficiary of combination optionality, but do not chase it as a direct beta play. The catalyst is indirect and slower; use only as a hedge if you want exposure to the partnership ecosystem without single-asset risk.
• Set a tactical stop on RLAY if the stock retraces below the pre-data breakout zone on heavy volume. That would signal the market is rejecting the new narrative and re-focusing on binary clinical risk.